ReviewAnalytical and bioanalytical chemistry2026
Overcoming sensitivity limitations in lateral flow immunoassays for small-molecule detection: from tracer engineering to assay format innovation.
Review in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Typical small-molecule contaminants such as mycotoxins, drug impurities, food additives, and antibiotics can enter living organisms through multiple pathways, which may cause a range of health problems. Timely detection of abnormalities in these small molecules is crucial for maintaining health. The lateral flow immunoassay (LFIA), as a simple, rapid, and intuitive detection method, allows for real-time analysis of samples and has become an indispensable tool for on-site screening. However, the sensitivity and robustness of traditional gold nanoparticles (AuNPs)-based LFIA remain insufficient for reliable detection in complex matrices, largely due to limitations in signal generation and assay architecture. This review critically analyzes the recent development of LFIA for small-molecule detection from two perspectives. Firstly, we focus on advances in assay format engineering, including oriented antigen-antibody coupling, heterologous coating approaches, and innovative non-competitive configurations, which collectively improve recognition efficiency and analytical performance. In addition, signal amplification strategies through tracer engineering are discussed, including surface modification, multivalent labeling strategies, and colorimetric- or fluorescence-based signal enhancement. For complex detection matrices, the incorporation of magnetic nanoparticles (MNPs) and surface-enhanced Raman scattering (SERS) has also been explored as an effective way to strengthen signal output. Finally, this article points out the technical limitations and future development trends, aiming to provide conceptual guidance for the rational design of next-generation LFIA.
Indexed as
Identifiers
42844450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.